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Abstract Primary synovial sarcoma outside its classical
presentation in para-articular soft tissue of young patients is
rare but regularly reported. One of the rarest primary lo-
cations is the lung.We describe a 73-year-old female patient
who presented with a solitary malignant bone tumor 8 years
after the resection of a lung neoplasm. The bone tumor was
classified as an osteosarcoma and the lung tumor as an
atypical carcinoid tumor at their first respective diagnostic
work-ups. The resection of the affected humerus with allo-
graft and endoprosthesis implantation followed. Reevalua-
tion of the tumor samples at the time of the local recurrence
of the bone tumor 6 years following the initial symptoms of
the bone tumor lead to the reclassification of both speci-
mens as synovial sarcomas. Both neoplasms contained the
SYT-SSX1 type of the diagnostic translocation t(X;18) as
detected by the reverse-transcription polymerase chain
reaction analysis. The patient died 14 years after the re-
section of the primary synovial sarcoma of the lung and
6 years following the occurrence of the bone metastasis.
This prolonged clinical course is uncommon for the SYT-
SSX1 translocation, which, in other locations, is usually
associated with an unfavorable prognosis.
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metastasis . Gene translocation
Introduction
Synovial sarcomas, which account for approximately 10%
of all malignant soft-tissue tumors, arise most commonly in
the para-articular tissues in adolescents and young adults
[13, 25]. It has become increasingly apparent, however, that
synovial sarcomas may arise in a wide variety of other sites,
including head and neck, mediastinum, heart, kidney,
prostate, esophagus and vulva, and that they also occur in
elderly patients [6]. There are four different morphological
subtypes of synovial sarcoma: biphasic, monophasic spin-
dle cell type, monophasic glandular type and poorly dif-
ferentiated. While the histological diagnosis of a classical
biphasic subtype is usually not difficult, the other types may
be confounded with many other entities, especially when
presenting in an unusual clinical context. The identification
of the specific cytogenetic alteration in form of a balanced
translocation t(X;18) with fusion product between SYTand
SSX genes allows reliable diagnosis and/or confirmation of
the diagnosis of a synovial sarcoma [13]. The correct
diagnosis leads to the institution of the proper treatment and
the estimation of prognostic factors. Although at present,
surgery is still the mainstay of the treatment of synovial
sarcomas and although there are no specific adjuvant
methods (except for the notion of better response to some
chemotherapy regimes), the situation may change in the
future. The results of molecular studies on the oncogenic
mechanism of the SYT-SSX fusion product [10, 11, 20] and
on the expression profiles of synovial sarcomas [1, 21] may
possibly allow the development of tumor-specific medica-
tions with the best candidate targeted at present being
epidermal growth factor receptor.
Spindle cell tumors of the lung fall into several prog-
nostically and pathogenetically different categories, such as
sarcomatous carcinomas, malignant mesotheliomas and
sarcomas. Primary sarcomas of the lung are exceedingly
rare and constitute about 0.1% of malignant lung tumors.
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Reports of primary synovial sarcomas of the lung and
pleura began to appear with increasing frequency in recent
years due to the potent diagnostic tools in the form of
immunohistochemistry and molecular genetics [5, 12, 18].
We present an unusual case of a late solitary bone
metastasis—at first erroneously diagnosed as an osteosar-
coma—occurring 8 years after a resection of a primary
pulmonary synovial sarcoma—at first erroneously diag-
nosed as an atypical carcinoid tumor—with confirmatory
molecular analysis of the SYT-SSX translocation. Thanks
to this examination, both tumors proved to represent
manifestations of the same disease (monophasic synovial
sarcoma), despite differing diagnoses in the preceding
biopsies.
Case report
A 73-year-old female patient presented in September 1995
with slowly progressive pain in her right shoulder and
weight loss. Within few weeks, the intensity of the pain
increased and was also present at night. Standard radio-
graphs obtained in December 1996 demonstrated an exten-
sive aggressive, osteolytic lesion in the proximal humerus
(Fig. 1A). Scintigraphically, no other bone lesions were
found. An incisional biopsy of the tumor was performed in
January 1996. The histological diagnosis was consistent
with small cell osteosarcoma. The thorough staging proce-
dure revealed no other tumormanifestations, specifically no
pulmonary or bone metastases. The patient rejected an
amputation, and the transarticular resection of the proximal
humerus with implantation of an allograft and endoprosthe-
sis was performed in January 1996 without direct com-
plications. The postoperative follow-up was uneventful,
with satisfying healing and no metastases radiologically.
In March 1998, 2 years later, standard radiographs and
computed tomography of the chest demonstrated small
pulmonary nodules compatible with metastatic spread. The
patient declined further diagnostic and therapeutic proce-
dures, and radiological follow-up showed slow progression
of the pulmonary findings. Local recurrence of the tumor in
the right humerus in August 2000, 4 years after the resection
of the proximal humerus, proved unresponsive to radiation
therapy. An accelerated growth as well as development of
exulcerated tumor necrosis prompted palliative resection in
December 2001. The patient died within 1 week of post-
operative cardiac complications, 14 years following the
resection of the pulmonary primary tumor. The patient was
a housewife, and her medical history was otherwise un-
eventful, except for a remote history of a cholecystectomy,
high blood pressure and slight aortic valve stenosis. No
autopsy was performed.
At review, the tumor tissue resected in December 2001 as
well as the previous histological specimens from this lo-
cation were strongly suggestive of a monophasic spindle
cell synovial sarcoma. The careful study of the patient file
revealed the history of an operation of a lung tumor 8 years
prior to the current onset of symptoms in the right shoulder
(Fig. 1B) with the histological diagnosis of an atypical
carcinoid tumor. At the time of the lung resection, no other
tumor manifestations were found clinically and radiologi-
cally. The slides and paraffin blocks of this tumor could be
recovered from another institution. The comparison of the
morphology, immunohistochemical properties and the sta-
tus of the t(X;18) proved identical tumor cell types mor-
phologically and immunohistochemically with the same
SYT-SSX1 translocation specific for synovial sarcoma.
Materials and methods
Clinical information was obtained from the files of the
medical facilities where the patient had been treated. The
study was performed in accordance with the guidelines of
the local ethics commission. Histological material from the
lung and bone tumors was fixed in buffered 4% formalin
Fig. 1 A Extensive osteolytic
tumor in the metaphysis of the
proximal right humerus (stan-
dard radiograph). B Proximally
located lung tumor resected
8 years prior to the presentation
of the bone lesion (standard
radiograph)
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and embedded in paraffin according to standard procedures.
Sections (1–2 μm) were cut for conventional histology
and immunohistochemistry. The following antibodies were
used: pan-cytokeratin (1:250; Biomedicals AG, Augst,
Switzerland), early membrane antigen (EMA, 1:20; Dako,
Glostrup, Denmark), S100 (1:3000; Dako), CD34 (1:50;
Serotec Ltd., Oxford, UK), synaptophysin (1:30; Dako),
chromogranin (1:50; Dako), alpha-smooth-muscle actin
(SMA) (1:20,000; Sigma, St. Louis, USA), desmin (1:20;
Dako). Immunohistochemistry was performed on deparaf-
finized sections using the Ventana NexES automated
staining system with diaminobenzidine as substrate. For
antigen retrieval, slides were either enzymatically predi-
gested or heated in citrate buffer for 3 min using a pressure
cooker. Slides were counterstained with hemalaum. The
quality of the reactions was controlled on tissue slides with
known reaction patterns stained in parallel with the ex-
amined probes.
Reverse-transcription polymerase chain reaction
RNA extraction and reverse-transcription polymerase chain
reaction (RT-PCR) analysis were performed as previously
described [14]. For subtyping SYT-SSX fusion transcripts,
3 µl of each PCR product was enzymatically hydrolyzed at
65°C for 1 h with 5 units of the restriction enzyme TaqI
(Roche Diagnostics) in a final volume of 10 µl. The di-
gestion patterns of the PCR products were analyzed on 2%
agarose gels and visualized using ethidium bromide stain-
ing. The size of digested products were 65 bp and 32 bp for
the SYT-SSX1 fusion gene transcripts, but remained at
97 bp for SYT-SSX2.
Subtyping was determined in parallel by single-strand
conformation polymorphism (SSCP) analysis. Aliquots of
5 µl of PCR products were mixed with 5 µl of denaturing
buffer (0.1 M NaOH and 2 mM ethylenediaminetetraac-
etate), heated at 50°C for 10 min. After addition of 1 µl of
formamide dye, the samples were immediately loaded
onto a 40% mutation detection enhancement (MDE) gel
(FMC BioProducts, Rockland, Maine USA) and electro-
phoresed in 0.5×Tris–borate–EDTA (TBE) buffer at 20°C
and 300 V (20 V/cm) for 5 h. The gels were stained with a
SYBR Gold gel stain (Molecular Probes, Eugene, OR,
USA) diluted 1:10,000 in 1×TBE buffer and visualized
under ultraviolet light using a charge-coupled device
camera.
Results
Pathological findings
Lung tumor (1987)
The resected right upper lobe contained a 3-cm whitish,
well-circumscribed tumor mass in the vicinity of a prox-
imal segmental bronchus without infiltration of the mu-
cosa. Microscopically, the tumor consisted of plump, oval
and spindle cells densely packed, partially infiltrating the
outer bronchial wall (Fig. 2A). Focally, a trabecular pattern
was found. The mitotic activity was 12 mitoses per 10
high power fields. No necrosis or lymph-node metastases
were found.
Bone tumor (1996 and 2001)
The incisional biopsy contained hypercellular tumor tissue
consisting of closely packed plump spindle and oval cells
with scant cytoplasm, indistinct cell borders, arranged in
irregularly intersecting fascicles or in a haphazard fashion.
There were some variably ramifying and gaping, thin-
walled vascular channels with a hemagiopericytoma-like
appearance. Small foci of ossification (Fig. 3A) were
present. Mitotic figures were easily found. The resected
proximal humerus contained a large tumor mass with a
longitudinal diameter of 8 cm, destroying the cortical bone
Fig. 2 Lung tumor. A Plump, relative monomorph spindle cells (hematoxylin and eosin ×10). B Intracytoplasmatic and nuclear expression
of S100 protein (×20)
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and minimally infiltrating the adjacent soft tissue. The
tumor tissue was similar to the biopsy material, but areas
with matrix hyalinization and slender spindle cells were
more prominent. No tumor necrosis except for the biopsy
site was noted. The recurrent tumor following radiother-
apy was partially necrotic, showing high mitotic activity
and somewhat stronger pleomorphism.
Immunohistochemistry
The lung tumor was negative for cytokeratin, EMA,
synaptophysin, chromogranin and showed focal positivity
for S100 (Fig. 2B). Contrary to the biopsy and resection
material of the bone tumor, the recurrence showed focal
positivity for cytokeratin and EMA. Focal positivity for
S100 was present in all bone tumor specimen (Fig. 3B).
Other markers remained negative.
RT-PCR for SYT-SSX translocation
SYT-SSX fusion transcripts were detected in both primary
lung tumor and humeral metastasis. Subtyping using
SSCP showed that both were of SYT-SSX1 type (Fig. 4).
Discussion
The definition of synovial sarcoma has strikingly changed
since its initial description in the beginning of the 20th
century. Due to its commonly para-articular location, the
tumor was initially falsely considered to originate from the
synovial lining of joints. The most recent definition of
synovial sarcoma includes the occurrence of a specific
genetic abnormality [13]. After observation of the trans-
location between chromosome X and 18 in synovial sar-
comas in 1986 [11], the fusion products of SYT-SSX with
its variants -SSX1, -SSX2 and -SSX4 were described, de-
pending on the SSX gene involved. The oncogenic po-
tential of this gene is currently a subject of many studies
[1, 10, 20, 21, 25]. The abnormalities mentioned above are
specific to synovial sarcoma and are found in more than
95% of this tumor type with isolated reports on related
cytogenetic abnormalities [23]. There are, at present, no
convincing reports of its occurrence in other tumor types
[4, 8, 14]. Thanks to the progress in molecular techniques,
the detection of the fusion product is currently possible on
standard pathological paraffin-embedded archive material
[2, 4]. According to several reports, synovial sarcomas in
unusual locations or in unusual clinical contexts have been
previously diagnosed under various names, such as “clas-
sical” soft tissue fibrosarcoma for cases of monophasic
fibrous synovial sarcoma [25] or embryonal sarcoma of
the kidney for renal monophasic synovial sarcomas [3].
In our patient, the difficulty in classifying the lung neo-
plasia resulted in the diagnosis of an atypical carcinoid
tumor.
Fig. 3 Humerus tumor. A Spindle and oval tumor cells with focal osteoid production (hematoxylin and eosin ×200). B Expressin of
cytokeratin by individual tumor cells (×400)
Fig. 4 Detection of the t(X;18) (SYT-SSX) translocation in the
primary lung tumor (lanes 1 and 2), in the humeral metastasis (lanes
3 and 4), using reverse-transcription polymerase chain reaction
(PCR). For each sample, two PCR amplifications were performed in
parallel, both containing the primer set necessary for the amplifi-
cation of SYT-SSX fusion gene transcripts and a set of primers for
the ubiquitously expressed β-actin gene transcripts (positive con-
trol). A biphasic synovial sarcoma was used as a positive control
(lane 5) for the t(X;18) detection. Negative control consisted of t
(X;18)-negative desmoid tumor. Lane 7 pGEM DNA size markers
(Promega Madison, WI)
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We present a case where a synovial sarcoma was not
considered as a diagnostic possibility either during the
primary presentation in the lung or during the work-up of
the solitary bone metastasis 8 years later. The examination
of the local recurrence of the bone metastasis with review
of all the slides and the molecular analysis of the SYT-
SSX fusion product allowed the diagnosis of a primary
lung synovial sarcoma. This tumor type is very rare, as the
primary in the lung. Only about 50–60 cases (most of them
monophasic spindle cell type and only two of the biphasic
type) have been recorded in the English-language litera-
ture [5, 12, 16, 18, 22, 24]. This probably underestimates
the prevalence of the disease, due to the diagnostic diffi-
culties in differentiating among various spindle cell tumors
of the lung. Many entities must be considered, namely
sarcomatous carcinoma, malignant mesothelioma, spindle
cell thymoma invading the lung, metastatic melanoma
or—in women—metastatic malignant mixed Müllerian
tumor and, of particular importance, metastatic sarcoma.
Other primary sarcoma types also occurring in the lung
must be taken into account, such as leiomyosarcoma,
malignant peripheral nerve sheath tumor, solitary fibrous
tumor, fibrosarcoma and mesenchymal chondrosarcoma.
The eventual diagnosis of a spindle cell tumor of the lung
depends in many cases on the results of the immunohis-
tochemical reactions and—if the synovial sarcoma is a
morphological consideration—on the molecular analysis.
Due to the small number of the described synovial
sarcomas of the lung, the course of the disease is not yet
fully known. There are only few reports with specific
reference to the SYT-SSX translocation type [5, 16, 22, 24].
Patients with the SYT-SSX2 translocation, generally con-
sidered to have a relatively favorable outcome [17, 19],
fared poorly and died within months. Most patients
(including the patient described in the current study) with
the SYT-SSX1 fusion product demonstrated a prolonged
disease course with survival of up to 14 years, but a few died
as early as at 12 months [16, 22, 24].
Synovial sarcoma in elderly patients is uncommon. Less
than 10% of synovial sarcomas occur in patients over
60 years. Chan et al. [6] analyzed 32 patients older than
60 years with synovial sarcoma. They concluded that the
tumors in this age group occur more often in unusual
locations and have more often poorly differentiated mor-
phology. Four of their cases were primaries of the lung, with
none being metastatic at 36–48 months of follow-up.
The possibility of a primary bone synovial sarcoma
presenting metachronously as lung tumor may theoretically
be considered in our patient. However, the long time lag
between both tumor presentations as well as the lacking
clinical skeletal symptoms at the time of the lung resection
make this possibility unlikely. Synovial sarcoma metasta-
sizes predominantly hematogenously, most commonly to
the lung (90–100% of the patients with metastases),
followed by lymph nodes (<10%) and, in rare cases, by
bone marrow [25]. At least two cases of a primary pul-
monary sarcoma have been reported as metastatic to bone
[16, 22]. A primary synovial sarcoma of bone is practically
unknown. Hiraga [15] describes a radius tumor with mor-
phological properties of a synovial sarcoma and the t(X;18)
translocation, but there is no mention of the past medical
history of the patient, and the possibility of a late metastasis
(as in our case) is not excluded. The tendency of the
synovial sarcoma for late metastases is well known and is
mirrored in marked differences between short- and long-
term survival [25]. The case of Cohen [7] probably rep-
resents a classical presentation of a synovial sarcoma in the
para-articular soft tissue of the knee of a 22-year-old man
with secondary infiltration of the tibia. Because no radio-
logical or pathological documentation is included, the
topography of the tumor cannot be definitively estimated.
The necessity of molecular testing in every case of a
synovial sarcoma has been discussed in the recent paper of
Coindre [9]. The authors conclude that this examination is
not required in every case. Diagnosing synovial sarcoma in
its classical biphasic form and/or classical clinical presen-
tation does not cause any difficulty. It is, however, more
problematic in its more common, monophasic spindle cell
variant or poorly differentiated type. Because, in many
cases, the immunohistochemistry is not sufficient, the
option of molecular testing represents a helpful alternative.
In conclusion, the presented case demonstrates that for
the proper understanding of the natural course of some of
the rare mesenchymal tumors, very long follow-ups must
be taken into account. The possibility of molecular testing
for the presence and type of the t(X;18) translocation is
valuable in the differential diagnosis of spindle cell malig-
nant tumors and allows precise classification of some of
them. Its role for the prognosis of the primary pulmonary
synovial sarcoma remains to be established.
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